Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.26B in total; Duquesne Family Office is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Monte Rosa Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 5 insiders, $963.1K in total
- Insiders trading
- 5
- Net value
- −$963.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Monte Rosa Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Warmuth Markus | President & CEO | 585,038 | Jul 17, 2026 | 7 |
| Champoux Jennifer | Chief Operating Officer | 62,371 | Jul 16, 2026 | 6 |
| Townson Sharon | Chief Scientific Officer | 67,845 | Jul 7, 2026 | 5 |
| Behbahani Ali | Director | 0Indirect | Jul 6, 2026 | 2 |
| Janku Filip | Chief Medical Officer | 60,612 | Jul 1, 2026 | 5 |
| Manning Anthony M. | Director | 0 | Jun 30, 2026 | 3 |
| Schiff Andrew N | Director | – | Jun 12, 2026 | 1 |
| Siu Christine | Director | – | Jun 12, 2026 | 1 |
| Blackwell Kimberly | Director | – | Jun 12, 2026 | 1 |
| Skvarka Jan | Director | – | Jun 12, 2026 | 1 |
| Hughes Eric A | Director | – | Jun 12, 2026 | 1 |
| Nickson Philip | Chief Business & Legal Officer | 55,000 | Apr 10, 2026 | 2 |
| Bowen Matthew | Principal Accounting Officer | 25,904 | Apr 7, 2026 | 1 |
| Dunn Edmund | Principal Accounting Officer | 22,554 | Mar 5, 2026 | 3 |
| Leo Chandra P. | Director | 10,000 | Mar 25, 2025 | 0 |
| Versant Venture Capital VI, L.P. | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Versant Vantage I, L.P. | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Versant Vantage I GP, L.P. | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Versant Ventures VI GP-GP, LLC | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Versant Vantage I GP-GP, LLC | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Versant Ventures VI GP, L.P. | 10% Owner | 1,573,453Indirect | Oct 30, 2024 | 0 |
| Wallace Owen B. | Chief Scientific Officer | – | Jan 4, 2024 | 0 |
| Jones Jullian G | Chief Business Officer | – | Jan 4, 2024 | 0 |
| Mayweg Alexander | Director | – | Jun 15, 2023 | 0 |
| Castle John C. | Chief Data Scientist | – | Jan 4, 2023 | 0 |
| Tamboli Ajim | Chief Financial Officer | – | Jan 4, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 17, 2026 (view filing)4:05 PM ET | Jul 16 | 1 day | Warmuth MarkusPresident & CEO | SSale | −9.50K | $23.18 | −$220.2K | −1.6%585.0K after | |
| Jul 16, 2026 (view filing)4:10 PM ET | Jul 15 | 1 day | Champoux JenniferChief Operating Officer | SSale | −4.35K | $23.38 | −$101.7K | −6.5%62.4K after | 10b5-1 |
| Jul 7, 2026 (view filing)4:41 PM ET | Jul 6 | 1 day | Townson SharonChief Scientific Officer | SSale | −6.00K | $23.31 | −$139.8K | −8.1%67.8K after | 2 lots10b5-1 |
| Jul 1, 2026 (view filing)4:57 PM ET | Jun 30 | 1 day | Janku FilipChief Medical Officer | SSale | −5.41K | $24.50 | −$132.5K | −8.2%60.6K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Janku FilipChief Medical Officer | SSale | −6.00K | $22.95 | −$137.7K | −9.1%60.0K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Manning Anthony M.Director | SSale | −10.0K | $23.11 | −$231.1K | −100.0%0 after | |
| Jun 25, 2026 (view filing) | Jun 23-24 | 2 days | Janku FilipChief Medical Officer | SSale | −41.8K | $21.08 | −$882.1K | −41.1%60.0K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Townson SharonChief Scientific Officer | SSale | −3.00K | $20.00 | −$60.0K | −4.2%67.8K after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Champoux JenniferChief Operating Officer | SSale | −2.17K | $20.00 | −$43.5K | −3.4%62.4K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Champoux JenniferChief Operating Officer | SSale | −2.18K | $19.00 | −$41.3K | −3.4%62.4K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Townson SharonChief Scientific Officer | SSale | −3.00K | $19.00 | −$57.0K | −4.2%67.8K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Warmuth MarkusPresident & CEO | SSale | −5.47K | $19.44 | −$106.2K | −0.9%594.5K after | 2 lots10b5-1 |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Townson SharonChief Scientific Officer | SSale | −6.00K | $19.87 | −$119.2K | −8.1%67.8K after | 10b5-1 |
| May 28, 2026 (view filing) | May 27 | 1 day | Champoux JenniferChief Operating Officer | SSale | −2.17K | $20.00 | −$43.5K | −3.4%62.4K after | 10b5-1 |
| May 26, 2026 (view filing) | May 22 | 4 days | Champoux JenniferChief Operating Officer | SSale | −2.18K | $19.00 | −$41.3K | −3.4%62.4K after | 10b5-1 |
| May 22, 2026 (view filing) | May 21 | 1 day | Manning Anthony M.Director | SSale | −10.0K | $18.01 | −$180.1K | −100.0%0 after | |
| May 5, 2026 (view filing) | May 1 | 4 days | Warmuth MarkusPresident & CEO | SSale | −5.47K | $18.92 | −$103.4K | −0.9%600.0K after | 10b5-1 |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Warmuth MarkusPresident & CEO | SSale | −8.00K | $17.64 | −$141.1K | −1.3%605.5K after | |
| Apr 10, 2026 (view filing) | Apr 9 | 1 day | Nickson PhilipChief Business & Legal Officer | SSale | −5.84K | $17.69 | −$103.4K | −9.6%55.0K after | |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Dunn EdmundPrincipal Accounting Officer | SSale | −139 | $17.96 | −$2.50K | −0.6%22.6K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Warmuth MarkusPresident & CEO | SSale | −5.47K | $17.92 | −$98.0K | −0.9%613.5K after | 10b5-1 |
| Mar 2, 2026 (view filing) | Feb 27-Mar 2 | 3 days | Dunn EdmundPrincipal Accounting Officer | SSale | −25.7K | $18.09 | −$464.8K | −53.1%22.7K after | 2 lots |
| Feb 24, 2026 (view filing) | Feb 23 | 1 day | Janku FilipChief Medical Officer | SSale | −9.19K | $19.50 | −$179.2K | −12.2%65.8K after | |
| Jan 9, 2026 (view filing) | Jan 7 | 2 days | Warmuth MarkusPresident & CEO | SSale | −5.47K | $23.48 | −$128.4K | −0.9%618.9K after | 3 lots10b5-1 |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Nickson PhilipChief Business & Legal Officer | SSale | −3.15K | $15.17 | −$47.9K | −4.9%60.8K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Champoux JenniferChief Operating Officer | SSale | −2.63K | $15.17 | −$39.9K | −4.0%62.4K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Dunn EdmundPrincipal Accounting Officer | SSale | −1.04K | $15.17 | −$15.8K | −4.4%22.7K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Warmuth MarkusPresident & CEO | SSale | −10.1K | $15.17 | −$153.7K | −1.6%624.4K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Janku FilipChief Medical Officer | SSale | −3.15K | $15.17 | −$47.9K | −4.0%75.0K after | |
| Jan 5, 2026 (view filing) | Jan 5 | Same day | Townson SharonChief Scientific Officer | SSale | −3.15K | $15.17 | −$47.9K | −4.4%67.8K after | |
| Jun 4, 2025 (view filing) | Jun 3 | 1 day | Dunn EdmundPrincipal Accounting Officer | SSale | −2.06K | $4.45 | −$9.18K | −8.0%23.7K after | |
| Mar 25, 2025 (view filing) | Mar 24 | 1 day | Leo Chandra P.Director | PPurchase | +10.0K | $5.84 | +$58.4K | New position10.0K after | |
| Oct 30, 2024 (view filing)4:35 PM ET | Oct 28-29 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −157.9K | $9.44 | −$1.49M | −9.1%1.57M after | 3 lots |
| Sep 24, 2024 (view filing)4:40 PM ET | Sep 20 | 4 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −1.13M | $6.53 | −$7.40M | −18.2%5.10M after | |
| Sep 13, 2024 (view filing)6:44 PM ET | Sep 11-13 | 2 days | Versant Venture Capital VI, L.P. and 5 others10% Owner | SSale | −567.2K | $6.00 | −$3.40M | −8.3%6.23M after | 3 lots |
| Jul 9, 2024 (view filing) | Jul 5 | 4 days | Dunn EdmundPrincipal Accounting Officer | SSale | −1.61K | $3.83 | −$6.17K | −10.4%13.9K after | |
| Jun 5, 2024 (view filing) | Jun 3 | 2 days | Dunn EdmundPrincipal Accounting Officer | SSale | −1.21K | $4.04 | −$4.88K | −7.2%15.6K after |